Novel contrast agents to enhance medical imaging

EU-funded researchers are working on novel, more effective contrast agents - the substances that make the contrast between, for example, muscle and bone, in MRI scans. This new level of detail will improve diagnostics and help ensure people receive the right treatment.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 17 November 2017  
Related theme(s) and subtheme(s)
Frontier research (ERC)
Health & life sciencesHealth & ageing  |  Molecular biology
Research policyHorizon 2020
Countries involved in the project described in the article
Austria  |  Poland  |  Slovenia  |  Sweden
Add to PDF "basket"

Novel contrast agents to enhance medical imaging

Picture of an woman with shoulder in pain

© Rambutano - fotolia.com

As Europe’s ageing population grows, so does the need for improved diagnostic and therapeutic treatments. Today, molecular imaging (MI) is indispensable to diagnosis, understanding disease and developing treatments. However, according to the EU-funded CONQUER project, magnetic resonance imaging (MRI) currently only plays a minor role in contrast media – despite its potential to improve molecular imaging techniques – because of the time and expense involved.

MRI scans are much better at looking at soft tissues – such as cartilage, nerves and organs – than CT scans or x-rays. Moreover, MRIs can complement these other examinations with additional information. MRI scans are particularly useful for identifying tumours, bleeding, blood vessel diseases or infection.

CONQUER will explore new contrast agents – the substances used in MI that enhance the contrast between structures or fluids within the body – to paint more accurate pictures of potential injury, infection or disease in patients. It will focus on one particular contrast mechanism called ‘quadrupole cross relaxation’ that is known to be extremely versatile and is able to enhance the contrast in molecular imaging. By making the image clearer, MRI scans will be able to provide more precise and detailed information about patients to their doctors.

If successful, CONQUER’s novel contrast media will have smart properties, such as the ability to switch the contrast on and off from afar, using a magnetic field. The techniques could also be used to develop specific and smart contrast media for a number of different diagnostic applications.

Europe is already the world leader in the development of contrast agents, but CONQUER’s potential to create imaging solutions could have a significant impact on modern diagnosis and treatment. The project results aim to provide a theoretical basis for further research, toxological references, guidelines and imaging instrumentation that will lay the foundations for developing new and innovative technology in the field.

Project details

  • Project acronym: CONQUER
  • Participants: Austria (Coordinator), Poland, Sweden, Slovenia
  • Project N°: 665172
  • Total costs: € 2 463 975
  • EU contribution: € 2 463 975
  • Duration: September 2015 to August 2018

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details